Passage Bio’s Growth Potential Highlighted by Clinical Progress and Regulatory Alignment
Yun Zhong from Wedbush has reiterated a Buy rating on Passage Bio, lowering the price target to $32.00. The rating reflects the company's significant clinical progress, particularly with the PBFT02 program targeting frontotemporal dementia (FTD). Key catalysts include ongoing patient enrollment and expected clinical updates in 2026. Passage Bio's alignment with the FDA and promising biomarker data further support its growth potential, alongside a solid cash runway into Q1 2027, leading to an optimistic outlook for the company.
Yun Zhong, an analyst from Wedbush, reiterated the Buy rating on Passage Bio. The associated price target was lowered to $32.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Yun Zhong has given his Buy rating due to a combination of factors that highlight Passage Bio’s potential for growth and success. The company is making significant progress in its clinical trials, specifically with the PBFT02 program, which targets frontotemporal dementia (FTD). The ongoing patient enrollment and anticipated clinical updates in the first half of 2026 are expected to act as strong catalysts for the stock.
Additionally, Passage Bio’s alignment with the FDA on manufacturing processes and the potential for a single-arm registrational study demonstrate the company’s proactive approach to regulatory hurdles. The promising biomarker data, including sustained CSF PRGN expression and reduced NfL levels, further support the potential efficacy of PBFT02. These factors, combined with a solid cash runway into the first quarter of 2027, underpin Yun Zhong’s optimistic outlook and the reiterated Outperform rating for Passage Bio.
